id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-0681-0007,FDA,FDA-2022-E-0681,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-18T04:00:00Z,2025,9,2025-09-18T04:00:00Z,,2025-09-19T00:46:47Z,,0,0,09000064b8fafed4
FDA-2022-E-0681-0006,FDA,FDA-2022-E-0681,Determination of Regulatory Review Period for Purposes of Patent Extension; BYLVAY,Notice,Determinations,2024-12-18T05:00:00Z,2024,12,2024-12-18T05:00:00Z,2025-02-19T04:59:59Z,2024-12-20T18:16:19Z,2024-29966,0,0,090000648687b50b
FDA-2022-E-0681-0005,FDA,FDA-2022-E-0681,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-11-01T04:00:00Z,2024,11,2024-11-01T04:00:00Z,,2024-11-01T13:33:22Z,,0,0,09000064867ec9c9
FDA-2022-E-0681-0004,FDA,FDA-2022-E-0681,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T19:10:51Z,,0,0,0900006486479691
FDA-2022-E-0681-0003,FDA,FDA-2022-E-0681,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T21:49:50Z,,0,0,09000064863ae229
FDA-2022-E-0681-0002,FDA,FDA-2022-E-0681,"Patent Extension Application from Fish & Richardson P.C. (on behalf of Albireo Pharma, Inc.)",Other,Application,2022-04-26T04:00:00Z,2022,4,2022-04-26T04:00:00Z,,2022-04-26T13:04:14Z,,0,0,0900006485035bdb
FDA-2022-E-0681-0001,FDA,FDA-2022-E-0681,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-04-26T04:00:00Z,2022,4,2022-04-26T04:00:00Z,,2022-04-26T13:04:08Z,,0,0,0900006485035bd9